HEDTUMSO
DEAD

Serial Number

90860790

Owner

Bristol-Myers Squibb Company

Attorney

Marilyn F. Kelly

Filing Date

Aug 2, 2021

Add to watchlist:

No watchlists yet
View on USPTO

HEDTUMSO Trademark

Serial Number: 90860790

HEDTUMSO is a trademark filed by Bristol-Myers Squibb Company on August 2, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Bristol-Myers Squibb Company (57 trademarks)

Route 206 & Province Line Road
Princeton, NJ 08543

Entity Type: 03

Trademark Details

Filing Date

August 2, 2021

Registration Date

Not Registered

Published for Opposition

January 17, 2023

Goods & Services

pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical and biological preparations for human use for immunotherapy, namely t cell therapy; pharmaceutical preparations for human use, namely, stem cells for medical use; pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Apr 20, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Apr 20, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2025 EXRA
SOU EXTENSION 5 GRANTED
Aug 29, 2025 EX5G
SOU TEAS EXTENSION RECEIVED
Aug 26, 2025 EEXT
SOU EXTENSION 5 FILED
Aug 25, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 11, 2025 EXRA
SOU EXTENSION 4 GRANTED
Mar 10, 2025 EX4G
SOU EXTENSION 4 FILED
Mar 10, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Mar 10, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 27, 2024 EXRA
SOU EXTENSION 3 GRANTED
Aug 27, 2024 EX3G
SOU EXTENSION 3 FILED
Aug 27, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Aug 27, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 9, 2024 EXRA
SOU EXTENSION 2 GRANTED
Feb 7, 2024 EX2G
SOU EXTENSION 2 FILED
Feb 7, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 7, 2024 EEXT
ITU LETTER MAILED, NO RESPONSE REQUIRED
Sep 8, 2023 IULN
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sep 8, 2023 AITU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 31, 2023 EXRA
SOU TEAS EXTENSION RECEIVED
Aug 29, 2023 EEXT
SOU EXTENSION 1 GRANTED
Aug 29, 2023 EX1G
SOU EXTENSION 1 FILED
Aug 29, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 29, 2023 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 14, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 17, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jan 17, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 28, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 12, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 8, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 8, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 8, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 8, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 25, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 25, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 25, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 26, 2022 GNRN
NON-FINAL ACTION E-MAILED
Apr 26, 2022 GNRT
NON-FINAL ACTION WRITTEN
Apr 26, 2022 CNRT
ASSIGNED TO EXAMINER
Apr 19, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 28, 2021 NWOS
NEW APPLICATION ENTERED
Aug 5, 2021 NWAP